Cite
HARVARD Citation
Smolen, J. et al. (n.d.). AB0765 Secukinumab provides sustained improvement in function, quality of life and fatigue over 2 years in patients who achieved disease activity index for psoriatic arthritis (DAPSA) remission. Annals of the rheumatic diseases. pp. 1322-1323. [Online].